Effects of Oxytocin on Reinforcement Learning

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-04

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main aim of the study is to investigate whether intranasal oxytocin (24IU) influences reward sensitivity and performance monitoring during reinforcement learning.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oxytocin Effects on the Tolerance of Infidelity

NCT02733237

Healthy

COMPLETED NA

Dose-dependent Effects of Oxytocin on the Amygdala and Reward System

NCT03846739

Healthy

COMPLETED PHASE1

Differential Effects of Oral and Intranasal Oxytocin on Attention Control

NCT04815395

Healthy

COMPLETED NA

The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )

NCT07140237

Healthy Adult Male

RECRUITING EARLY_PHASE1

Effects of Intranasal Oxytocin on Emotion Regulation

NCT03055546

Healthy

UNKNOWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A double-blind, within-subject, placebo-controlled pharmacological EEG design will be employed. A total of 35 healthy male subjects will be recruited which will receive either intranasal placebo or oxytocin (24IU) on two separate study days (order counter-balanced, washout period at least 2 weeks). 45 minutes after treatment subjects will undergo a probabilistic feedback reinforcement learning paradigm with concurrent EEG acquisition. During the paradigm subjects will learn the reward probabilities of two different visual stimuli from probabilistic feedback provided by social stimuli (positive, negative emoticon). The paradigm includes an initial acquisition phase and a subsequent test phase.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Learning Disabilities

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized placebo-controlled double-blind within-subject design

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oxytocin then placebo

Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo.

Group Type EXPERIMENTAL

intranasal oxytocin

Intervention Type DRUG

24 IU of oxytocin nasal spray will be applied to each subject.

intranasal placebo

Intervention Type DRUG

an identical amount of placebo nasal spray will be applied to each subject.

Placebo then oxytocin

Participants first receive placebo. After a washout period of 2 weeks, they receive oxytocin (24 IU).

Group Type EXPERIMENTAL

intranasal oxytocin

Intervention Type DRUG

24 IU of oxytocin nasal spray will be applied to each subject.

intranasal placebo

Intervention Type DRUG

an identical amount of placebo nasal spray will be applied to each subject.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intranasal oxytocin

24 IU of oxytocin nasal spray will be applied to each subject.

Intervention Type DRUG

intranasal placebo

an identical amount of placebo nasal spray will be applied to each subject.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18-30
* Male sex
* Right handedness

Exclusion Criteria

* History of brain injury
* Current or history of psychiatric, neurological or internist disorder
* Current or regular use of medication, psychotropic substances, including nicotine
* Contraindications for Oxytocin

Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes